Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics

Cancer statistics, 2016

Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003 · see citing works

Microtubules as a target for anticancer drugs

Jordan, M. A., & Wilson, L. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1317 · Cited by 4,534 · see citing works

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · see citing works

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796 · see citing works

Metformin: from mechanisms of action to therapies

Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501 · see citing works

BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo

Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M. P., Krššák, M., Gürtler, U., Garin‐Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 845 · see citing works

An overview of doxorubicin formulations in cancer therapy

Rivankar, S. (2014) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.139267 · Cited by 749 · see citing works

Bora and the Kinase Aurora A Cooperatively Activate the Kinase Plk1 and Control Mitotic Entry

Seki, A., Coppinger, J. A., Jang, C., Yates, J. R., & Fang, G. (2008) · Science · doi:10.1126/science.1157425 · Cited by 622 · see citing works

Shared and separate functions of polo-like kinases and aurora kinases in cancer

Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597 · see citing works

Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles

Sunkel, C. E., & Glover, D. M. (1988) · Journal of Cell Science · doi:10.1242/jcs.89.1.25 · Cited by 563 · see citing works

Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells

Liu, X., & Erikson, R. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031523100 · Cited by 474 · see citing works

Metabolic flux and the regulation of mammalian cell growth

Locasale, J. W., & Cantley, L. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.07.014 · Cited by 449 · see citing works

Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Darshan, M. S., Loftus, M. S., Thadani‐Mulero, M., Levy, B. P., Escuín, D., Zhou, X. K., Gjyrezi, A., Chanel‐Vos, C., Shen, R., Tagawa, S. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1417 · Cited by 429 · see citing works

Targeted therapies: a new generation of cancer treatments.

Gerber, D. E. (2008) · PubMed · Cited by 419 · see citing works

Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State

Garcı́a-Cao, I., Song, M. S., Hobbs, R. M., Laurent, G., Giorgi, C., de Boer, V. C. J., Anastasiou, D., Ito, K., Sasaki, A. T., Rameh, L. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.030 · Cited by 403 · see citing works

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J., Haslinger, C., Garin‐Chesa, P., & Adolf, G. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2445 · Cited by 402 · see citing works

CLIP-170 Highlights Growing Microtubule Ends In Vivo

Perez, F., Diamantopoulos, G. S., Stalder, R., & Kreis, T. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80656-x · Cited by 397 · see citing works

Polo-like kinases (Plks) and cancer

Takai, N., Hamanaka, R., Yoshimatsu, J., & Miyakawa, I. (2005) · Oncogene · doi:10.1038/sj.onc.1208272 · Cited by 391 · see citing works

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent

Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J. G., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 374 · see citing works

Implication of cell kinetic changes during the progression of human prostatic cancer.

Berges, R. R., Vukanovic, J., Epstein, J. I., CarMichel, M., Cisek, L. J., Johnson, D. E., Veltri, R. W., Walsh, P. C., & Isaacs, J. T. (1995) · PubMed · Cited by 342 · see citing works

The same, only different – DNA damage checkpoints and their reversal throughout the cell cycle

Shaltiël, I. A., Krenning, L., Bruinsma, W., & Medema, R. H. (2015) · Journal of Cell Science · doi:10.1242/jcs.163766 · Cited by 289 · see citing works

Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5

Golsteyn, R. M., Schultz, S. J., Bártek, J., et al. (1994) · Journal of Cell Science · doi:10.1242/jcs.107.6.1509 · Cited by 279 · see citing works

From Plk1 to Plk5

de Cárcer, G., Manning, G., & Malumbres, M. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16494 · Cited by 273 · see citing works

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Döhner, H., Lübbert, M., Fiedler, W., Fouillard, L., Haaland, A. K., Brandwein, J. M., Leprêtre, S., Reman, O., Turlure, P., Ottmann, O. G., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560557 · Cited by 233 · see citing works

Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions

Reindl, W., Yuan, J., Krämer, A., Strebhardt, K., & Berg, T. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.03.013 · Cited by 233 · see citing works

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology

Schöffski, P. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0010 · Cited by 230 · see citing works

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

Gjertsen, B. T., & Schöffski, P. (2014) · Leukemia · doi:10.1038/leu.2014.222 · Cited by 225 · see citing works

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

Burger, H., van Tol, H., Brok, M. O., et al. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.1826 · Cited by 207 · see citing works

Topors Functions as an E3 Ubiquitin Ligase with Specific E2 Enzymes and Ubiquitinates p53

Rajendra, R., Malegaonkar, D., Pungaliya, P., Marshall, H., Rasheed, Z. A., Brownell, J. E., Liu, L. F., Lutzker, S. G., Saleem, A., & Rubin, E. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400300200 · Cited by 192 · see citing works

Topors acts as a SUMO‐1 E3 ligase for p53 in vitro and in vivo

Weger, S., Hammer, E., & Heilbronn, R. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.07.088 · Cited by 186 · see citing works

Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality

Spratt, D. E., Zhang, C., Zumsteg, Z. S., Pei, X., Zhang, Z., & Zeléfsky, M. J. (2012) · European Urology · doi:10.1016/j.eururo.2012.12.004 · Cited by 180 · see citing works

Polo-like kinase 1 reaches beyond mitosis—cytokinesis, DNA damage response, and development

Takaki, T., Trenz, K., Costanzo, V., & Petronczki, M. P. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.10.005 · Cited by 176 · see citing works

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

Liu, X. (2015) · Translational Oncology · doi:10.1016/j.tranon.2015.03.010 · Cited by 172 · see citing works

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

Olmos, D., Barker, D. S., Sharma, R., Brunetto, A. T., Yap, T. A., Taegtmeyer, A. B., Barriuso, J., Medani, H., Degenhardt, Y., Allred, A. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2946 · Cited by 169 · see citing works

Plk1 regulates mitotic Aurora A function through βTrCP-dependent degradation of hBora

Chan, E. H., Santamaría, A., Silljé, H. H. W., & Nigg, E. A. (2008) · Chromosoma · doi:10.1007/s00412-008-0165-5 · Cited by 160 · see citing works

Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus

Thadani‐Mulero, M., Nanus, D. M., & Giannakakou, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0783 · Cited by 146 · see citing works

Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

Gilmartin, A. G., Bleam, M. R., Richter, M. C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0945 · Cited by 134 · see citing works

Plk1 and Mps1 Cooperatively Regulate the Spindle Assembly Checkpoint in Human Cells

von Schubert, C., Cubizolles, F., Bracher, J. M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.007 · Cited by 132 · see citing works

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

O’Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J. M., Coveler, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv264 · Cited by 130 · see citing works

Prognostic significance of polo-like kinase expression in esophageal carcinoma.

Tokumitsu, Y., Mori, M., Tanaka, S., et al. (1999) · International Journal of Oncology · doi:10.3892/ijo.15.4.687 · Cited by 126 · see citing works

Plk5, a Polo Box Domain-Only Protein with Specific Roles in Neuron Differentiation and Glioblastoma Suppression

de Cárcer, G., Escobar, B., Higuero, A. M., Garcia, L. A. L., Ansón, A., Pérez, G., Mollejo, M., Manning, G., Meléndez, B., Abad‐Rodríguez, J., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.00607-10 · Cited by 119 · see citing works

Plk1 Inhibition Enhances the Efficacy of Androgen Signaling Blockade in Castration-Resistant Prostate Cancer

Zhang, Z., Hou, X., Shao, C., Li, J., Cheng, J., Kuang, S., Ahmad, N., Ratliff, T. L., & Liu, X. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1916 · Cited by 109 · see citing works

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

Stadler, W. M., Vaughn, D. J., Sonpavde, G., Vogelzang, N. J., Tagawa, S. T., Petrylak, D. P., Rosen, P. J., Lin, C., Mahoney, J. F., Modi, S., et al. (2013) · Cancer · doi:10.1002/cncr.28519 · Cited by 106 · see citing works

Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer

Song, B., Liu, X. S., Liu, X. S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0632 · Cited by 102 · see citing works

Polo‐like kinase 1 phosphorylation of G2 and S‐phase‐expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery

Liu, X., Li, H., Song, B., & Liu, X. S. (2010) · EMBO Reports · doi:10.1038/embor.2010.90 · Cited by 99 · see citing works

Role for Plk1 phosphorylation of Hbo1 in regulation of replication licensing

Wu, Z.-Q., & Liu, X. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712063105 · Cited by 98 · see citing works

Polo-Box Domain Inhibitor Poloxin Activates the Spindle Assembly Checkpoint and Inhibits Tumor Growth in Vivo

Yuan, J., Sanhaji, M., Krämer, A., Reindl, W., Hofmann, M., Kreis, N., Zimmer, B., Berg, T., & Strebhardt, K. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.06.031 · Cited by 98 · see citing works

Plk1 Phosphorylation of PTEN Causes a Tumor-Promoting Metabolic State

Li, Z., Li, J., Bi, P., Lü, Y., Burcham, G. N., Elzey, B. D., Ratliff, T. L., Konieczny, S. F., Ahmad, N., Kuang, S., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00814-14 · Cited by 96 · see citing works

Phosphorylation of CLIP‐170 by Plk1 and CK2 promotes timely formation of kinetochore–microtubule attachments

Li, H., Liu, X. S., Liu, X. S., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.174 · Cited by 92 · see citing works

Plk1-mediated Phosphorylation of Topors Regulates p53 Stability

Yang, X., Li, H., Zhou, Z., Wang, W., Deng, A., ANDRISANI, O. M., & Liu, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.c109.001560 · Cited by 89 · see citing works

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

Mross, K. B., Dittrich, C., Aulitzky, W. E., Strumberg, D., Schütte, J., Schmid, R. M., Hollerbach, S., Merger, M., Munzert, G. M., Fleischer, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.257 · Cited by 86 · see citing works

Overexpression of Polo-Like Kinase 1 (PLK1) and Chromosomal Instability in Bladder Cancer

Yamamoto, Y., Matsuyama, H., Kawauchi, S., Matsumoto, H., Nagao, K., Ohmi, C., Sakano, S., Furuya, T., Oga, A., Naito, K., et al. (2006) · Oncology · doi:10.1159/000094416 · Cited by 86 · see citing works

Opportunities and challenges in combination gene cancer therapy

Nastiuk, K. L., & Krolewski, J. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.005 · Cited by 85 · see citing works

Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours

Frost, A., Mross, K. B., Steinbild, S., et al. (2012) · Current Oncology · doi:10.3747/co.19.866 · Cited by 83 · see citing works

Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors

Beria, I., Ballinari, D., Bertrand, J. A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901713n · Cited by 82 · see citing works

TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens

Hikichi, Y., Honda, K., Hikami, K., Miyashita, H., Kaieda, I., Murai, S., Uchiyama, N., Hasegawa, M., Kawamoto, T., Sato, T., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0762 · Cited by 81 · see citing works

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

Lin, C.-C., Su, W., Yen, C.-J., Hsu, C., Su, W.-P., Yeh, K.-H., Lu, Y., Cheng, A.-L., Huang, D. C.-L., Fritsch, H., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.195 · Cited by 80 · see citing works

Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation

Forrest, R. A., Swift, L. P., Rephaeli, A., Nudelman, A., Kimura, K., Phillips, D. R., & Cutts, S. M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.02.026 · Cited by 78 · see citing works

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Bowles, D. W., Diamond, J. R., Lam, E. T., Weekes, C. D., Astling, D. P., Anderson, R. T., Leong, S., Gore, L., Varella‐Garcia, M., Vogler, B. W., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2506 · Cited by 75 · see citing works

Polo-like Kinase 1 Facilitates Loss of Pten Tumor Suppressor-induced Prostate Cancer Formation

Liu, X. S., Song, B., Elzey, B. D., Ratliff, T. L., Konieczny, S. F., Liang Cheng, C., Ahmad, N., & Liu, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c111.269050 · Cited by 73 · see citing works

Plk1 Phosphorylation of Orc2 Promotes DNA Replication under Conditions of Stress

Song, B., Liu, X. S., Davis, K. M., & Liu, X. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.06110-11 · Cited by 73 · see citing works

Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells

Scharow, A., Raab, M., Saxena, K., et al. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00565 · Cited by 68 · see citing works

Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia

Rudolph, D., Impagnatiello, M. A., Blaukopf, C., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.221150 · Cited by 66 · see citing works

hGTSE-1 Expression Stimulates Cytoplasmic Localization of p53

Monte, M., Benetti, R., Collavin, L., Marchionni, L., Sal, G. D., & Schneider, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311123200 · Cited by 62 · see citing works

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma

Posch, C., Cholewa, B. D., Vujic, I., Sanlorenzo, M., Ma, J., Kim, S. T., Kleffel, S., Schatton, T., Rappersberger, K., Gutteridge, R., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.198 · Cited by 59 · see citing works

Spatiotemporal dynamics of Aurora B-PLK1-MCAK signaling axis orchestrates kinetochore bi-orientation and faithful chromosome segregation

Shao, H., Huang, Y., Zhang, L., Yuan, K., Chu, Y., Dou, Z., Jin, C., Garcia-Barrio, M. T., Liu, X., & Yao, X. (2015) · Scientific Reports · doi:10.1038/srep12204 · Cited by 58 · see citing works

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes

Komrokji, R. S., Raza, A., Lancet, J. E., Ren, C., Taft, D. R., Maniar, M. L., Wilhelm, F. E., & List, A. F. (2013) · British Journal of Haematology · doi:10.1111/bjh.12436 · Cited by 57 · see citing works

Chorioretinal Folds: Associated Disorders and a Related Maculopathy

Olsen, T. W., Palejwala, N. V., Lee, L. B., et al. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.02.021 · Cited by 53 · see citing works

Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)

Nie, Z., Feher, V. A., Natala, S. R., McBride, C. M., Kiryanov, A. A., Jones, B., Lam, B., Liu, Y., Kaldor, S. W., Stafford, J. A., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.083 · Cited by 50 · see citing works

Polo-like kinase 1 phosphorylation of p150 Glued facilitates nuclear envelope breakdown during prophase

Li, H., Liu, X. S., Yang, X., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006615107 · Cited by 49 · see citing works

Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer's disease

Song, B., Davis, K. M., Liu, X. S., Lee, H., Smith, M. A., & Liu, X. (2011) · Aging · doi:10.18632/aging.100382 · Cited by 49 · see citing works

ATM and the Mre11-Rad50-Nbs1 Complex Respond to Nucleoside Analogue–Induced Stalled Replication Forks and Contribute to Drug Resistance

Ewald, B., Sampath, D., & Plunkett, W. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0971 · Cited by 48 · see citing works

Pregnancy's Fast Flame for the Flu

Schubert, C. (2014) · Biology of Reproduction · doi:10.1095/biolreprod.114.125542 · Cited by 47 · see citing works

A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors

de Braud, F., Cascinu, S., Spitaleri, G., Pilz, K., Clementi, L., Liu, D., Sikken, P., & Pas, T. M. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv354 · Cited by 45 · see citing works

Metformin for cancer prevention: a reason for optimism

Chan, A. T. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00006-1 · Cited by 45 · see citing works

Inhibition of Polo-like Kinase 1 (Plk1) Enhances the Antineoplastic Activity of Metformin in Prostate Cancer

Shao, C., Ahmad, N., Hodges, K. B., Kuang, S., Ratliff, T., & Liu, X. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.596817 · Cited by 40 · see citing works

Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1

Wu, C., Hsiao, S.-H., Sim, H., Luo, S.-Y., Tuo, W.-C., Cheng, H.-W., Li, Y., Huang, Y.-H., & Ambudkar, S. V. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.004 · Cited by 39 · see citing works

In vitro targeting of Polo-like kinase 1 in bladder carcinoma

Brassesco, M. S., Pezuk, J. A., Morales, A. G., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.25087 · Cited by 38 · see citing works

The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia

Casolaro, A., Golay, J., Albanese, C., Ceruti, R., Patton, V., Cribioli, S., Pezzoni, A., Losa, M., Texidó, G., Giussani, U., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058424 · Cited by 35 · see citing works

Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance

Sero, V., Tavanti, E., Vella, S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0158-6 · Cited by 34 · see citing works

Plk1 Phosphorylates Sgt1 at the Kinetochores To Promote Timely Kinetochore-Microtubule Attachment

Liu, X. S., Song, B., Tang, J., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00516-12 · Cited by 33 · see citing works

Targeting prostate cancer cell lines with polo‐like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors

Wissing, M. D., Mendonca, J., Kortenhorst, M. S. Q., Kaelber, N. S., Gonzalez, M., Kim, E., Hammers, H. J., van Diest, P. J., Carducci, M. A., & Kachhap, S. K. (2013) · The FASEB Journal · doi:10.1096/fj.12-222893 · Cited by 33 · see citing works

Abiraterone in Metastatic Prostate Cancer

Ryan, C. J., Molina, A., & Griffin, T. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1301594 · Cited by 33 · see citing works

Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma

Stehle, A., Hugle, M., & Fulda, S. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.011 · Cited by 31 · see citing works

Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1

Wu, C., Hsieh, C., Hsiao, S.-H., Luo, S.-Y., Su, C.-Y., Li, Y., Huang, Y.-H., Huang, C., & Hsu, S.-C. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00312 · Cited by 31 · see citing works

Plk1‐dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer

Hou, X., Li, Z., Huang, W., et al. (2013) · The Prostate · doi:10.1002/pros.22683 · Cited by 29 · see citing works

Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer

Zhang, Z., Chen, L., Wang, H., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1041689 · Cited by 28 · see citing works

Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP‐binding Domain or Polo‐box Domain

Shin, S., Woo, S., & Yim, H. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25042 · Cited by 23 · see citing works

Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis

Czaplinski, S., Hugle, M., Stiehl, V., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3901 · Cited by 20 · see citing works

PLK1 regulates spindle formation kinetics and APC/C activation in mouse zygote

Baran, V., Brzáková, A., Rehák, P., et al. (2015) · Zygote · doi:10.1017/s0967199415000246 · Cited by 19 · see citing works

PLK4 Is Essential for Meiotic Resumption in Mouse Oocytes1

Luo, Y.-B., & Kim, N. (2015) · Biology of Reproduction · doi:10.1095/biolreprod.114.124065 · Cited by 18 · see citing works

Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression

Nair, J. S., & Schwartz, G. K. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1078033 · Cited by 13 · see citing works

Plk1 phosphorylation of Topors is involved in its degradation

Yang, X., Li, H., Deng, A., et al. (2009) · Molecular Biology Reports · doi:10.1007/s11033-009-9871-1 · Cited by 11 · see citing works

PLK-1 inhibition improves abiraterone efficacy

Thoma, C. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.287 · Cited by 9 · see citing works

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment

Chiappa, M., Petrella, S., Damia, G., Broggini, M., Guffanti, F., & Ricci, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903016 · Cited by 120 · see citing works

USP7 Is a Master Regulator of Genome Stability

Valles, G. J., Bezsonova, I., Woodgate, R., & Ashton, N. W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00717 · Cited by 114 · see citing works

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity

Wright, G., Golubeva, V., Remsing Rix, L. L., Berndt, N., Luo, Y., Ward, G. A., Gray, J. E., Schonbrunn, E., Lawrence, H. R., Monteiro, A. N. A., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00147 · Cited by 77 · see citing works

The enhancement of siPLK1 penetration across BBB and its anti glioblastoma activity in vivo by magnet and transferrin co-modified nanoparticle

Liu, D.-Z., Cheng, Y., Cai, R.-Q., Wang, B., Cui, H., Liu, M., Zhang, B.-L., Mei, Q.-B., & Zhou, S.-Y. (2018) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.01.004 · Cited by 66 · see citing works

Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives

Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65 · see citing works

The role of polo‐like kinase 3 in the response of BRAF‐mutant cells to targeted anticancer therapies

Babagana, M., Kichina, J. V., Slabodkin, H., Johnson, S., Maslov, A., Brown, L., Attwood, K., Nikiforov, M. A., & Kandel, E. S. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23123 · Cited by 12 · see citing works

DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION

Mustafa, N. H., Kelesbayev, D., & Alibekova, Z. D. (2018) · The Journal of Economic Research & Business Administration · doi:10.26577/be-2018-2-2141

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

Genentech taps Affimed’s antibodies

Cross, R. (2018) · C&EN Global Enterprise · doi:10.1021/cen-09635-buscon15

KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK

Sari, D. (2023) · Jurnal Komplikasi Anestesi · doi:10.22146/jka.v5i1.7322

Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria

Dib, A., Puig, L. B., Salvadori, D., et al. (1988) · Arquivos Brasileiros de Cardiologia